Following the announcement of our recent collaboration with China-based biotech company, Hangzhou DAC, Dan Wang, Regional Head, Johnson & Johnson Innovation, Asia Pacific, sat down with Peter Lebowitz, Global Oncology Therapeutic Area Head, the Janssen Pharmaceutical Companies of Johnson & Johnson, to discuss the collaboration opportunities for oncology in China and the Asia Pacific. Here’s what he had to say:
Cancer remains the leading cause of death globally and in China and it’s not something we can tackle alone. It is vital that we look not only inside but outside in the ecosystem. We are proud of our recent collaborations and work to advance new solutions in this space, but the work is far from over.
“There is true innovation coming out of China as well as the rest of Asia and the danger of being a large company is that sometimes you think you can do it all, and the truth is that even at The Johnson & Johnson Family of Companies, the largest healthcare company in the world, we can't do it all”
If you’re working on an early-stage healthcare innovation and interested in connecting with us to discuss potential collaboration, incubation and investment opportunities, get in touch: